GPRC5D and Miyoshi myopathy: Recent 2025 multi-omics studies highlight epigenetic drivers of antigen escape in immunotherapy-resistant MM, such as promoter methylation changes in BCMA and GPRC5D, underscoring the need for epigenome-targeted therapies [13,73].